Aurinia Pharmaceuticals Inc. announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program. Economic modeling by the Institute for Clinical and Economic Review (ICER) in March 2021 demonstrated the cost-effectiveness of LUPKYNIS in adults with active lupus nephritis (LN).

An updated cost-effectiveness analysis demonstrated that LUPKYNIS continues to be a cost-effective treatment for lupus nephritis ("LN"). Cost-effectiveness was assessed with the ICER AnalyticsTM LN model and the majority of model assumptions from the original analysis were consistent with the 2021 analysis. Updated inputs in this new analysis included the 2023 cost of LUPKYNIS, the duration of treatment for people who did not respond to treatment, and the cost of treating LN patients with end-stage kidney disease.

LUPKYNIS is the first U.S. Food and Drug Administration and European Commission approved oral medicine for the treatment of adult patients with active lupus nePHritis (LN). LUPKYNIS is a second generation calcineur in inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The AURORA Clinical Program, comprised of the AURORA 1 pivotal trial and AURORA 2 extension trial, demonstrated the importance of LUPKYNIS plus standard of care to preserve kidney health in patients with active LN without reliance on chronic high-dose glucocorticoids.

It is the only clinical program to include three years of LN treatment and follow-up with mycophenolate mofetil (MMF) and steroids. Lupus Nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. LN affects approximately 120,000 people in the U.S. and disproportionately affects women and people of color.

Medical guidelines recommend that all SLE patients receive routine LN screenings at every visit. Guidelines also note that delaying LN diagnosis has profound prognostic consequences. Yet, research shows that approximately 50% of SLE patients are not screened for LN and 77% of people with LN go untreated.

Aurinia is committed to improving health outcomes for people living with LN by educating patients and providers on the critical need for routine screening and transformative therapies that can help improve health outcomes.